Chiesi investing 400 million euros in new biotech center

Family-controlled Italian drugmaker Chiesi Group yesterday celebrated the operational launch of its Biotech Center of Excellence.

This state-of-the-art facility is dedicated to developing and producing monoclonal antibodies, enzymes, and other proteins.

According to the company, this facility is anticipated to be outstanding in Europe for its integrated approach, housing the entire supply chain under one roof. From the production of drug substances from mammalian cells to their transformation into drug products and final packaging, everything will be done in a single location. The new site’s seamless integration of research and industrial production capabilities will be a major advantage, enabling more efficient transitions from development to manufacturing and significantly enhancing Chiesi’s ability to innovate and bring new treatments to market.